The authors declare no competing financial interests directly related to the content of this manuscript. E.D`A. is an employee of Roche Pharma Research and Early Development. R.L. and T.F.D. report scientific advisory and consultancy activities in the field of anti-TSHR antibodies unrelated to this work. M.B. reports research support from the Deutsche Krebshilfe and the Roux Program (Halle). F.F. is employed by OmnilinX Therapeutics AG. All other authors declare no conflicts of interest.
Anne Eugster
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Anne
Contact Anne, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack